Primary Mediastinal Large B-cell Lymphoma (PMBCL) Clinical Trial
Official title:
Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study by the Fondazione Italiana Linfomi.
The present study consists of a retrospective multicentric collection of all consecutive patients with PMBCL diagnosed over the time period considered (13 years, from 2007 to 2019 inclusive).
The study was initially set up as a spontaneous, non-profit study, with ARNAS Garibaldi of Catania (PI Dr Ugo Consoli) as the proposer. Subsequently, the project was expanded to include additional centres belonging to the Italian Lymphoma Foundation, which became the promoter in collaboration with ARNAS Garibaldi of Catania. The information collected is aimed at verifying the application in a "real world" context of the PMBCL diagnosis and therapy protocols suggested in the guidelines and at checking whether they produce results in line with those expected. The therapies considered for the I line of treatment are those described in the literature for the pathology under consideration: - R-CHOP14; R-CHOP21 and R-CHOP like, (R-CHOP: rituximab - cyclophosphamide, doxorubicin, vincristine, prednisone) - R-VACOPB, R-MACOPB and R-VACOPB like, MACOPB like, (R-VACOP-B: Rituximab - etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin. R-MACOP-B: Rituximab - methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) - R-DA-EPOCH ed R-EPOCH like (DA-R- EPOCH: Dose Adjusted - Rituximab - Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04526834 -
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT06339255 -
Italian Observational Study on CAR-T Therapy for Lymphoma
|
||
| Recruiting |
NCT06026319 -
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05934448 -
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
|
Phase 2 | |
| Recruiting |
NCT04186520 -
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04836507 -
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04875195 -
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
|
Phase 2 | |
| Active, not recruiting |
NCT03625037 -
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06024694 -
Primary Mediastinal Large B-cell Lymphoma With CNS Involvement
|
||
| Not yet recruiting |
NCT06208735 -
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT05856708 -
CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
|
||
| Completed |
NCT05130489 -
CAR T Cell Therapy Related Cardiovascular Outcomes
|
||
| Not yet recruiting |
NCT05934084 -
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
|
N/A | |
| Recruiting |
NCT04745559 -
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT04600947 -
Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05366569 -
Bio-CAR-T BS Study
|
||
| Recruiting |
NCT06014762 -
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
|
Phase 1 | |
| Approved for marketing |
NCT05733650 -
Expanded Access Program for Epcoritamab
|